- Home
- Aesthetic gynaecology
- Vaginal atrophy
- Vaginal oestrogen
Vaginal oestrogen: is it safe? What the studies say
The fear of vaginal oestrogen comes mainly from studies of systemic hormone therapy. See how much is absorbed, what the large studies show and when the decision belongs to the oncologist.
Quando existir, entra aqui e também no cartão da página do blog.
In this article
Vaginal oestrogen is the treatment with the most evidence for vaginal dryness and genitourinary syndrome of menopause (NAMS, 2020, Lethaby et al., 2016). Even so, many women hesitate to use it, or give up after reading the patient information leaflet, for fear of breast cancer, thrombosis or stroke.
This fear comes mainly from studies of systemic hormone therapy, that is, tablets and patches that deliver hormones to the whole body. Low-dose vaginal oestrogen works differently, and the studies that have evaluated it directly are reassuring.
Three ideas to remember.
Fica por baixo do resumo, se existir uma segunda foto.
Where the fear comes from
In 2002, the Women's Health Initiative (WHI) study showed that systemic hormone therapy, in tablet form, was associated with a small increase in the risk of breast cancer, thrombosis and stroke in some women. These results were widely publicised and the warnings were carried over into the leaflets of all oestrogen-containing medicines, including those for vaginal use.
The problem is that the WHI did not study vaginal oestrogen. The warnings were applied as a precaution, not because there were data showing these risks with local treatment (NAMS, 2020).
How much oestrogen reaches the blood
Vaginal oestrogen comes as a cream, pessaries, vaginal tablets, gel and vaginal ring. Low-dose formulations act mainly on the lining of the vagina, the vulva and the urethra.
Studies that measured blood levels show that, with low doses, oestradiol generally remains within the normal values for a postmenopausal woman (Santen, 2015). In the first weeks, while the lining is thin, absorption may be slightly higher; as the lining recovers, it decreases.
This is very different from systemic therapy, whose very purpose is to raise hormone levels throughout the body.
What the large studies say
Two large cohort studies followed tens of thousands of women who used vaginal oestrogen for years and compared them with women who did not (Crandall et al., 2018, Bhupathiraju et al., 2019).
| Risk assessed | What they found |
|---|---|
| Breast cancer | no increase in risk (Crandall et al., 2018, Bhupathiraju et al., 2019) |
| Endometrial cancer | no increase in risk (Crandall et al., 2018, Bhupathiraju et al., 2019, Constantine et al., 2019) |
| Stroke | no increase in risk (Crandall et al., 2018, Bhupathiraju et al., 2019) |
| Venous thrombosis and pulmonary embolism | no increase in risk (Crandall et al., 2018, Bhupathiraju et al., 2019) |
| Heart attack and cardiovascular disease | no increase in risk (Crandall et al., 2018, Bhupathiraju et al., 2019) |
These are observational studies, not randomised trials, so they do not prove that there is no risk at all. But, together with the absorption data, they have led scientific societies to consider low-dose vaginal oestrogen a safe treatment for most women (NAMS, 2020).
Do I need to take progesterone?
With systemic therapy, women who have a uterus need progesterone to protect the endometrium. With low-dose vaginal oestrogen, the available data do not show an increased risk of thickening or cancer of the endometrium, and progesterone is generally not needed (NAMS, 2020, Constantine et al., 2019). What is essential is to have any vaginal bleeding that appears during treatment assessed.
And after breast cancer?
This is where the decision is most delicate, and it should always be made together with the oncology team (ACOG, 2021).
- First option: hormone-free vaginal lubricants and moisturisers.
- If they are not enough: vaginal oestrogen can be considered, especially when symptoms greatly affect quality of life (ACOG, 2021).
- What the studies say: large cohort studies have not found an increase in breast cancer mortality among survivors who used vaginal oestrogen (Cold et al., 2022, McVicker et al., 2024). In a Danish study, however, an increased risk of recurrence was observed in women taking aromatase inhibitors (Cold et al., 2022). That is why, in these women, the decision needs even more care.
Never start vaginal oestrogen on your own if you have had breast cancer.
Side effects
Side effects are generally mild and local (Lethaby et al., 2016):
- burning or irritation in the first few days, especially with creams;
- increased discharge;
- small amounts of bleeding;
- breast tenderness, which is rare.
The initial burning usually passes as the lining recovers. If it persists, or if there is bleeding, talk to your doctor.
Who should not use it without assessment
- women with vaginal bleeding of unexplained cause;
- women with a history of breast or endometrial cancer;
- women with a history of thrombosis or stroke, who should discuss the treatment with their doctor, although the low-dose data are reassuring.
How long can it be used for?
Because the lack of oestrogen persists, symptoms tend to come back when treatment stops. Current recommendations do not set a time limit for low-dose vaginal oestrogen: it can be used for as long as there is benefit, with periodic review by the doctor (NAMS, 2020).
The usual regimen starts with one application a day for about two weeks, followed by maintenance 2 to 3 times a week. The dose and formulation are decided by the doctor.
When to see a doctor
If you have any doubts about the symptoms, call SNS 24 (808 24 24 24). In case of heavy bleeding, chest pain, sudden shortness of breath, pain and swelling in one leg or signs of a stroke (mouth drooping to one side, weakness in an arm, difficulty speaking), call 112.
At Luxmed Clinic
At the gynaecological aesthetics consultation, we assess the symptoms and medical history, examine the vulva and the vagina and explain the treatment options, with and without hormones, and what the evidence says about each one.
If you have had breast cancer or have other relevant conditions, we work together with your oncologist or own doctor before any decision.
Talk to us
The assessment is a conversation, with no obligation. Tell us what concerns you and our team will reply.
This article is for information only and does not replace a medical assessment. Results vary from person to person.
Frequently asked questions
Does vaginal oestrogen cause breast cancer?
The large studies of low-dose vaginal oestrogen have not found an increased risk of breast cancer. The warnings in the leaflets come mainly from studies of systemic hormone therapy.
Does vaginal oestrogen make you put on weight?
There is no evidence that low-dose vaginal oestrogen causes weight gain, given the small amount that reaches the blood.
What is the difference between vaginal oestriol and oestradiol?
They are two types of oestrogen used in vaginal formulations. Both are effective at a low dose. The choice depends on the formulation available and on the doctor's assessment.
Do I need a prescription?
Yes. Vaginal oestrogen is a prescription-only medicine.
Can I use it if I have had a thrombosis?
With a low dose, studies do not show an increased risk of thrombosis, but the decision should be made with your doctor, who will assess your case.
Can I use it for years?
Yes, for as long as there is benefit and with periodic review. Symptoms tend to come back when treatment is stopped.
Can my partner be affected during intercourse?
With creams, there may be some transfer. As a precaution, apply them at bedtime and not immediately before intercourse, or prefer formulations such as vaginal tablets or a ring.
Scientific references 9
- The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. Guideline
- Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500. Revisão Cochrane
- Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121-34. Artigo
- Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018;25(1):11-20. Artigo
- Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. Menopause. 2019;26(6):603-10. Artigo
- Constantine GD, Graham S, Lapane K, et al. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause. 2019;26(7):800-7. Artigo
- American College of Obstetricians and Gynecologists. Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: Clinical Consensus No. 2. Obstet Gynecol. 2021;138(6):950-60. Guideline
- Cold S, Cold F, Jensen MB, et al. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347-54. Artigo
- McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2024;10(1):103-8. Artigo
Keep exploring


